Perflubron (1-Bromoperfluorooctane, Perfluorooctyl bromide, Oxygent, PFOB) exhibits anti-inflammatory activity thus decreases cytokine production in human alveolar macrophages. Perflubron also attenuates oxidative damage to both biological and nonbiological systems which is independent of its anti-inflammatory properties.
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Sabah Servaes, et al. Pediatr Radiol. Perflubron residua: 12 years following therapy
 Jean-Damien Ricard, et al. Crit Care Med. Perflubron dosing affects ventilator-induced lung injury in rats with previous lung injury
 P E Keipert. Anasthesiol Intensivmed Notfallmed Schmerzther. Perflubron emulsion (Oxygent(tm)): a temporary intravenous oxygen carrier
 D R Spahn, et al. Anesthesiology. Perflubron emulsion delays blood transfusions in orthopedic surgery. European Perflubron Emulsion Study Group
 M J Thomassen, et al. Crit Care Med. Perflubron decreases inflammatory cytokine production by human alveolar macrophages
|Related Immunology/Inflammation Products|
Fucoxanthin is a carotenoid that occurs naturally in certain algae with anti-obesity, anti-oxidant, anti-diabetic, anticancer and anti-inflammatory activities.
TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway.
MRE-269(ACT-333679) is a prostaglandin I2 (IP) receptor agonist with a binding affinity for the human IP receptor that is 130-fold greater than that for other human prostanoid receptor.
Loxoprofen Sodium is a nonsteroidal anti-inflammatory drug (NSAID) in the propionic acid derivatives group
PMX-53 is a potent CD88 (C5aR) antagonist that inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.